Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing, with data expected mid-year 2023 Phase 3 registrational trial of TP-03 in Chinese patients with Demodex blepharitis ongoing, with data expected in the fourth quarter of 2023 Entered into commercial agreement with Pfizer, with Pfizer […]
Author: Ken Dropiewski
MEDINBOX PARTNERS WITH ABBOTT TO IMPROVE CONNECTIONS AND INFORMATION SHARING BETWEEN PHYSICIANS IN ELECTROPHYSIOLOGY LABS WORLDWIDE
EnSite™ Connected Care from Abbott will integrate with Medinbox’s smart video collaboration system to provide electrophysiologists with remote, real-time audiovisual support to improve case results Abbott’s exclusive global distribution agreement in electrophysiology market consolidates Medinbox’s position as major player in live medical collaboration and hospital digitization Toulouse, France, March 27, […]
Medtronic Announces Pricing of $2.0 Billion of Senior Notes
DUBLIN, March 23, 2023 /PRNewswire/ — Medtronic plc (the “Company”) (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. (“Medtronic Luxco”), has priced an offering (the “Offering”) of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000,000 principal amount of 4.50% senior notes due 2033 (collectively, the “Notes”). All of Medtronic Luxco’s obligations […]
Getinge recieves FDA premarket approval for the iCast™ covered stent system in the US
GOTHENBURG, Sweden, March 24, 2023 /PRNewswire/ — Getinge’s iCast™ covered stent system has received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with iliac arterial occlusive disease. Iliac arterial occlusive disease is a type of peripheral arterial disease (PAD), a serious condition that only in the US […]
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
— Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients — Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results – — Conference call and live webcast at 8:00 a.m. ET today […]
BioSig Announces New Advisory Board Member Lorraine Spurge
Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of Lorraine Spurge, entrepreneur and financier, to its Advisory […]
JanOne Welcomes John Bonfiglio — Veteran Biotech Executive, Deal Maker and Strategist — to Top Management Team
Bonfiglio is known for raising capital, building start-ups, and leading successful biotech companies as CEO and COO. LAS VEGAS, March 23, 2023 /PRNewswire/ — JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the hiring of John N. Bonfiglio, PhD, as interim […]
Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases
Widely Published Interventional Radiologist Has Earned Well-Regarded Reputation Working with Prestigious Medical Centers in the U.S. and Europe The addition of Professor O’Sullivan, the Clinical Director of Radiology for the Galway Clinic in Ireland, Expands the Company’s EU Presence. HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global […]
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
– Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement – – Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late […]
Acticor Biotech Publishes Its 2022 Annual Results and Provides an Update on Its Clinical Progress
Key milestones achieved in the two Phase 2/3 studies in stroke with glenzocimab: ACTISAVE study: more than 240 patients enrolled to date GREEN study: enrollment of the first patients Exchanges between the University of Birmingham and the UK regulatory authorities for the LIBERATE study in the treatment of myocardial infarction […]
